A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Presbyopia

In brief

Study of safety and efficacy of UNR844 in subjects with presbyopia.

Key facts

Study ID

NCT04806503

Run by

Novartis Pharmaceuticals

People needed

234

Starts

2021-06-30

Expected to finish

2022-10-14

Last updated by the study team

2024-06-20

Who can join

Age: 45 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent must be obtained before any assessment is performed
• Impaired near vision in each eye and when using both eyes, without any near correction
• Need a certain level of near correction

You may not qualify if…

• Impaired distance vision in either eye, with distance correction (if any)
• Severe short- or long-sightedness
• Any significant medical or clinical conditions affecting vision, the eyes or general health

Where it is running

• Novartis Investigative Site — Laguna Hills, California, United States
• Novartis Investigative Site — Newport Beach, California, United States
• Novartis Investigative Site — Newport Beach, California, United States
• Novartis Investigative Site — Largo, Florida, United States
• Novartis Investigative Site — Lake Villa, Illinois, United States
• Novartis Investigative Site — Pittsburg, Kansas, United States
• Novartis Investigative Site — Washington, Missouri, United States
• Novartis Investigative Site — Kingston, Pennsylvania, United States
• Novartis Investigative Site — Sioux Falls, South Dakota, United States
• Novartis Investigative Site — Memphis, Tennessee, United States
• Novartis Investigative Site — Smyrna, Tennessee, United States
• Novartis Investigative Site — San Antonio, Texas, United States
• Novartis Investigative Site — Sydney, New South Wales, Australia
• Novartis Investigative Site — East Melbourne, Victoria, Australia
• Novartis Investigative Site — Vancouver, British Columbia, Canada
• Novartis Investigative Site — Kitchener, Ontario, Canada
• Novartis Investigative Site — Waterloo, Ontario, Canada
• Novartis Investigative Site — Québec, Quebec, Canada
• Novartis Investigative Site — Suita, Osaka, Japan
• Novartis Investigative Site — Shinjuku Ku, Tokyo, Japan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.